| Characteristics . | All patients, n = 63 . |
|---|---|
| Age at time of operation (years) | 65 (55–71) |
| Male, n (%) | 40 (63) |
| BMI (kg/m2) | 27 (24–30) |
| Concomitant diseases, n (%) | |
| Hyperlipidaemia | 31 (50) |
| Smoking | 23 (37) |
| Arterial hypertension | 32 (52) |
| Diabetes | 18 (29) |
| Coronary artery disease | 43 (69) |
| Atrial fibrillation | 19 (31) |
| proBNP (ng/l) | 2098 (1054–5005) |
| NYHA III–IV, n (%) | 52 (83) |
| Ischaemic MR, n (%) | 42 (67) |
| FMR due to dilated cardiomyopathy, n (%) | 21 (33) |
| Echocardiographic parameters | |
| Baseline LVEF (%) | 35 (30–40) |
| LVEDD (mm) | 61 (55–65) |
| TAPSE (mm) | 18 (16–20) |
| Pulmonary artery pressure (mmHg) | 55 (44–58) |
| Cardiac MRI parameters | |
| Tenting height (mm) | 12 (10–14) |
| Annular diameter (mm) | 36 (33–41) |
| Tenting area (mm2) | 218 (165–267) |
| Ant. tenting angle (°) | 33 (29–37) |
| Post. tenting angle (°) | 39 (34–46) |
| IPMD (mm) | 26 (22–29) |
| PMAD (mm) | 31 (27–34) |
| LVEDVi (ml/BSA) | 122 (97–144) |
| LVESVi (ml/BSA) | 84 (59–99) |
| LVSVi (ml/BSA) | 42 (33–49) |
| LVEF (%) | 36 (29–40) |
| LVEDD (mm) | 65 (61–71) |
| LVESD (mm) | 52 (46–61) |
| Characteristics . | All patients, n = 63 . |
|---|---|
| Age at time of operation (years) | 65 (55–71) |
| Male, n (%) | 40 (63) |
| BMI (kg/m2) | 27 (24–30) |
| Concomitant diseases, n (%) | |
| Hyperlipidaemia | 31 (50) |
| Smoking | 23 (37) |
| Arterial hypertension | 32 (52) |
| Diabetes | 18 (29) |
| Coronary artery disease | 43 (69) |
| Atrial fibrillation | 19 (31) |
| proBNP (ng/l) | 2098 (1054–5005) |
| NYHA III–IV, n (%) | 52 (83) |
| Ischaemic MR, n (%) | 42 (67) |
| FMR due to dilated cardiomyopathy, n (%) | 21 (33) |
| Echocardiographic parameters | |
| Baseline LVEF (%) | 35 (30–40) |
| LVEDD (mm) | 61 (55–65) |
| TAPSE (mm) | 18 (16–20) |
| Pulmonary artery pressure (mmHg) | 55 (44–58) |
| Cardiac MRI parameters | |
| Tenting height (mm) | 12 (10–14) |
| Annular diameter (mm) | 36 (33–41) |
| Tenting area (mm2) | 218 (165–267) |
| Ant. tenting angle (°) | 33 (29–37) |
| Post. tenting angle (°) | 39 (34–46) |
| IPMD (mm) | 26 (22–29) |
| PMAD (mm) | 31 (27–34) |
| LVEDVi (ml/BSA) | 122 (97–144) |
| LVESVi (ml/BSA) | 84 (59–99) |
| LVSVi (ml/BSA) | 42 (33–49) |
| LVEF (%) | 36 (29–40) |
| LVEDD (mm) | 65 (61–71) |
| LVESD (mm) | 52 (46–61) |
Data are median (IQR) or n (%).
BMI: body mass index; BSA: body surface area; FMR: functional mitral regurgitation; IPMD: interpapillary muscle distance; IQR: interquartile range; LVEDD/LVESD: left ventricular end-diastolic and end-systolic diameters; LVEDVi/LVESVi: left ventricular end-systolic and end-diastolic volume index; LVEF: left ventricular ejection fraction; LVSVi: left ventricular stroke volume index; MR: mitral regurgitation; NYHA: New York Heart Association; PMAD: papillary muscle to mitral annulus distance; TAPSE: tricuspid annular plane systolic excursion.
| Characteristics . | All patients, n = 63 . |
|---|---|
| Age at time of operation (years) | 65 (55–71) |
| Male, n (%) | 40 (63) |
| BMI (kg/m2) | 27 (24–30) |
| Concomitant diseases, n (%) | |
| Hyperlipidaemia | 31 (50) |
| Smoking | 23 (37) |
| Arterial hypertension | 32 (52) |
| Diabetes | 18 (29) |
| Coronary artery disease | 43 (69) |
| Atrial fibrillation | 19 (31) |
| proBNP (ng/l) | 2098 (1054–5005) |
| NYHA III–IV, n (%) | 52 (83) |
| Ischaemic MR, n (%) | 42 (67) |
| FMR due to dilated cardiomyopathy, n (%) | 21 (33) |
| Echocardiographic parameters | |
| Baseline LVEF (%) | 35 (30–40) |
| LVEDD (mm) | 61 (55–65) |
| TAPSE (mm) | 18 (16–20) |
| Pulmonary artery pressure (mmHg) | 55 (44–58) |
| Cardiac MRI parameters | |
| Tenting height (mm) | 12 (10–14) |
| Annular diameter (mm) | 36 (33–41) |
| Tenting area (mm2) | 218 (165–267) |
| Ant. tenting angle (°) | 33 (29–37) |
| Post. tenting angle (°) | 39 (34–46) |
| IPMD (mm) | 26 (22–29) |
| PMAD (mm) | 31 (27–34) |
| LVEDVi (ml/BSA) | 122 (97–144) |
| LVESVi (ml/BSA) | 84 (59–99) |
| LVSVi (ml/BSA) | 42 (33–49) |
| LVEF (%) | 36 (29–40) |
| LVEDD (mm) | 65 (61–71) |
| LVESD (mm) | 52 (46–61) |
| Characteristics . | All patients, n = 63 . |
|---|---|
| Age at time of operation (years) | 65 (55–71) |
| Male, n (%) | 40 (63) |
| BMI (kg/m2) | 27 (24–30) |
| Concomitant diseases, n (%) | |
| Hyperlipidaemia | 31 (50) |
| Smoking | 23 (37) |
| Arterial hypertension | 32 (52) |
| Diabetes | 18 (29) |
| Coronary artery disease | 43 (69) |
| Atrial fibrillation | 19 (31) |
| proBNP (ng/l) | 2098 (1054–5005) |
| NYHA III–IV, n (%) | 52 (83) |
| Ischaemic MR, n (%) | 42 (67) |
| FMR due to dilated cardiomyopathy, n (%) | 21 (33) |
| Echocardiographic parameters | |
| Baseline LVEF (%) | 35 (30–40) |
| LVEDD (mm) | 61 (55–65) |
| TAPSE (mm) | 18 (16–20) |
| Pulmonary artery pressure (mmHg) | 55 (44–58) |
| Cardiac MRI parameters | |
| Tenting height (mm) | 12 (10–14) |
| Annular diameter (mm) | 36 (33–41) |
| Tenting area (mm2) | 218 (165–267) |
| Ant. tenting angle (°) | 33 (29–37) |
| Post. tenting angle (°) | 39 (34–46) |
| IPMD (mm) | 26 (22–29) |
| PMAD (mm) | 31 (27–34) |
| LVEDVi (ml/BSA) | 122 (97–144) |
| LVESVi (ml/BSA) | 84 (59–99) |
| LVSVi (ml/BSA) | 42 (33–49) |
| LVEF (%) | 36 (29–40) |
| LVEDD (mm) | 65 (61–71) |
| LVESD (mm) | 52 (46–61) |
Data are median (IQR) or n (%).
BMI: body mass index; BSA: body surface area; FMR: functional mitral regurgitation; IPMD: interpapillary muscle distance; IQR: interquartile range; LVEDD/LVESD: left ventricular end-diastolic and end-systolic diameters; LVEDVi/LVESVi: left ventricular end-systolic and end-diastolic volume index; LVEF: left ventricular ejection fraction; LVSVi: left ventricular stroke volume index; MR: mitral regurgitation; NYHA: New York Heart Association; PMAD: papillary muscle to mitral annulus distance; TAPSE: tricuspid annular plane systolic excursion.
This PDF is available to Subscribers Only
View Article Abstract & Purchase OptionsFor full access to this pdf, sign in to an existing account, or purchase an annual subscription.
